Sodium Lactate Infusion in GLUT1DS Patients

Study Overview
=================
Brief Summary
-----------------
This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.

Detailed Description
-----------------
In glucose transporter 1 deficiency syndrome (GLUT1DS) cerebral glucose uptake from the systemic blood circulation is limited, because of deficient transport of glucose across the blood-brain barrier by the transporter protein (GLUT1). Classically patients present with developmental problems, movement disorders and severe epilepsy. There is no curative treatment for GLUT1DS, and anti-epileptic drugs usually have little to no effect. The ketogenic diet, providing ketones as an alternative energy substrate for the brain is an effective treatment option for the epilepsy and movement disorders in many GLUT1DS patients. Unfortunately, not in all GLUT1DS patients the ketogenic diet has a positive effect and other treatment options for these patients are very limited. Traditionally, lactate is seen as a waste product of glycolysis during anaerobic conditions and a marker of ischemia. Interestingly, research has shown the beneficial side of lactate as an energy source for different organs. It seems that the brain can indeed use lactate as an alternative energy metabolite, besides glucose and ketones. The aim of this study is to investigate whether lactate can be an alternative energy metabolite in the GLUT1DS brain, and reduce epileptic discharges on EEG when intravenously administered in patients with GLUT1DS.

Official Title
-----------------
Effects of Sodium Lactate Infusion in Patients With Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)

Conditions
-----------------
GLUT1 Deficiency Syndrome, GLUT1DS1, GLUT1DS2, Epilepsy, Lactic Acid Blood Increased, Ketogenic Dieting

Intervention / Treatment
-----------------
* Other: sodiumlactate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with GLUT1DS and known in our center. Baseline characteristics include a high frequency of clinical seizures and epileptic discharges on EEG. History of trying ketogenic diet with good compliance without beneficial effects. Age > 6 years. Informed consent. Exclusion Criteria: Additional medical condition or illness that impairs the patient's ability to participate in the study (for example actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant haematological or biochemical abnormalities). Elevated serum sodium (> 145 mmol/L). Participation in another interventional study at start of the study or during the study. Presence of known panic disorders or a history of panic attacks.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Single center, interventional, explorative, open label, proof of principle study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits. | Other: sodiumlactate<br>* intravenous sodiumlactate 600mmol/L<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of changes in epileptic discharges on EEG during the infusion of lactate. | All subjects have frequent epileptic discharges on EEG. We want to objectify the change in epileptic discharges on EEG during and after the infusion of sodium lactate. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in seizure frequency clinical visible by caregivers during and after infusion of sodium lactate. | All subjects have frequent seizures, we want to see if these clinically visible seizures reduce during or after infusion with sodium lactate. | 1 day | 
| Concentration of lactate in blood during and after sodium lactate infusion |  | 1 day | 
| Concentration of glucose in blood during and after sodium lactate infusion |  | 1 day | 
| Concentration of sodium in blood during and after sodium lactate infusion |  | 1 day | 
| Concentration of potassium in blood during and after sodium lactate infusion |  | 1 day | 
| Concentration of bicarbonate in blood during and after sodium lactate infusion |  | 1 day | 
| Concentration of chloride in blood during and after sodium lactate infusion |  | 1 day | 
| pH in blood during and after sodium lactate infusion |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GLUT1 deficiency syndrome, sodium lactate infusion, epilepsy